

Number of participants included at each time point

BNT162b2

ChAdOx1 nCoV-19

FALSE

TRUE

Biologic

Infliximab

Vedolizumab

400
300
200
100
0

-20 -10 0 10 20 30

Weeks since second dose of vaccine

400
300
200
100
0

-20 -10 0 10 20 30

-20 -10 0 10 20 30